Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 8/20 | 0.55 |
| ▸ | PLAU | P00749 | 6/20 | 0.55 |
| ▸ | MMP2 | P08253 | 6/20 | 0.51 |
| ▸ | MMP1 | P03956 | 4/20 | 0.51 |
| ▸ | MMP3 | P08254 | 4/20 | 0.51 |
| ▸ | MMP13 | P45452 | 4/20 | 0.51 |
| ▸ | MMP7 | P09237 | 3/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19187443 | 0.92 | HPN (0.54) | HPNPLAUMMP2MMP1MMP3 | |
| SCHEMBL12435189 | 0.89 | MMP1 (0.48) | HPNPLAUMMP2MMP1MMP3 | |
| SCHEMBL12467275 | 0.85 | ADAM17 (0.47) | HPNPLAUMMP2MMP1MMP3 | |
| SCHEMBL12401646 | 0.82 | MMP2 (0.36) | HPNPLAUMMP2MMP1MMP3 | |
| SCHEMBL12435216 | 0.80 | MMP2 (0.35) | HPNPLAUMMP2MMP1MMP3 | |
| SCHEMBL19187604 | 0.79 | MMP2 (0.43) | HPNPLAUMMP2MMP1MMP3 | |
| SCHEMBL12435248 | 0.77 | ALDH1A1 (0.49) | MMP2MMP3 | |
| SCHEMBL464269 | 0.75 | ALDH1A1 (0.47) | MMP2MMP3TSHR | |
| SCHEMBL8285470 | 0.74 | PLAU (0.42) | HPNPLAU | |
| SCHEMBL12435214 | 0.73 | AAK1 (0.40) | MMP2MMP1MMP3MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528922-B1 | POLYHETEROCYCLIC COMPOUNDS AS HCV INHIBITORS | AB PHARMA LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | HPN 218/4885PLAU 2785/4885MMP2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.